Cargando…
How Much Should be Invested in Lung Care Across the WHO European Region? Applying a Monetary Value to Disability-Adjusted Life-Years Within the International Respiratory Coalition’s Lung Facts
OBJECTIVES: The International Respiratory Coalition’s Lung Facts web resource provides the latest data on a range of lung conditions covering the World Health Organization’s European Region, informed by the Global Burden of Disease studies: https://international-respiratory-coalition.org/lung-facts/...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232602/ https://www.ncbi.nlm.nih.gov/pubmed/37039953 http://dx.doi.org/10.1007/s40258-023-00802-y |
_version_ | 1785052018797182976 |
---|---|
author | Franklin, Matthew Angus, Colin Welte, Tobias Joos, Guy |
author_facet | Franklin, Matthew Angus, Colin Welte, Tobias Joos, Guy |
author_sort | Franklin, Matthew |
collection | PubMed |
description | OBJECTIVES: The International Respiratory Coalition’s Lung Facts web resource provides the latest data on a range of lung conditions covering the World Health Organization’s European Region, informed by the Global Burden of Disease studies: https://international-respiratory-coalition.org/lung-facts/. Within Lung Facts, disability-adjusted life-years (DALYs) are monetised based on gross domestic product (GDP) per capita. We describe the conceptual and empirical basis for using monetised DALYs to inform negotiations with policymakers to invest in lung care across the World Health Organization European region. METHODS: We reflect on the existing debate and research evidence regarding the X value in an X*GDP per capita framework to monetise DALYs, with a focus on if 1*GDP per capita is conceptually and practically appropriate. Using an asthma case study, Global Burden of Disease study 2019 DALY estimates per country are presented. Gross domestic product per capita are converted to international dollars using purchasing power parity (Int$2019). RESULTS: Using 1*GDP per capita, the estimated monetised asthma DALY burden, for example, in Kyrgyzstan or Germany is: across the whole population, $44,860,483 or $9,264,767,882, respectively; per 100,000 people, $731,600 or $10,208,317, respectively. CONCLUSIONS: Our indicative monetised DALY estimates can enable informed discussions with policy and decision makers, to guide financial investment in alleviating the burden of lung conditions. We suggest 1*GDP per capita as a benchmarked value forms a starting point for negotiation with policymakers for investing in lung care, by scaling the estimated lung condition DALY burden to the resource available in each country to tackle the burden. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40258-023-00802-y. |
format | Online Article Text |
id | pubmed-10232602 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-102326022023-06-02 How Much Should be Invested in Lung Care Across the WHO European Region? Applying a Monetary Value to Disability-Adjusted Life-Years Within the International Respiratory Coalition’s Lung Facts Franklin, Matthew Angus, Colin Welte, Tobias Joos, Guy Appl Health Econ Health Policy Practical Application OBJECTIVES: The International Respiratory Coalition’s Lung Facts web resource provides the latest data on a range of lung conditions covering the World Health Organization’s European Region, informed by the Global Burden of Disease studies: https://international-respiratory-coalition.org/lung-facts/. Within Lung Facts, disability-adjusted life-years (DALYs) are monetised based on gross domestic product (GDP) per capita. We describe the conceptual and empirical basis for using monetised DALYs to inform negotiations with policymakers to invest in lung care across the World Health Organization European region. METHODS: We reflect on the existing debate and research evidence regarding the X value in an X*GDP per capita framework to monetise DALYs, with a focus on if 1*GDP per capita is conceptually and practically appropriate. Using an asthma case study, Global Burden of Disease study 2019 DALY estimates per country are presented. Gross domestic product per capita are converted to international dollars using purchasing power parity (Int$2019). RESULTS: Using 1*GDP per capita, the estimated monetised asthma DALY burden, for example, in Kyrgyzstan or Germany is: across the whole population, $44,860,483 or $9,264,767,882, respectively; per 100,000 people, $731,600 or $10,208,317, respectively. CONCLUSIONS: Our indicative monetised DALY estimates can enable informed discussions with policy and decision makers, to guide financial investment in alleviating the burden of lung conditions. We suggest 1*GDP per capita as a benchmarked value forms a starting point for negotiation with policymakers for investing in lung care, by scaling the estimated lung condition DALY burden to the resource available in each country to tackle the burden. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40258-023-00802-y. Springer International Publishing 2023-04-11 2023 /pmc/articles/PMC10232602/ /pubmed/37039953 http://dx.doi.org/10.1007/s40258-023-00802-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Practical Application Franklin, Matthew Angus, Colin Welte, Tobias Joos, Guy How Much Should be Invested in Lung Care Across the WHO European Region? Applying a Monetary Value to Disability-Adjusted Life-Years Within the International Respiratory Coalition’s Lung Facts |
title | How Much Should be Invested in Lung Care Across the WHO European Region? Applying a Monetary Value to Disability-Adjusted Life-Years Within the International Respiratory Coalition’s Lung Facts |
title_full | How Much Should be Invested in Lung Care Across the WHO European Region? Applying a Monetary Value to Disability-Adjusted Life-Years Within the International Respiratory Coalition’s Lung Facts |
title_fullStr | How Much Should be Invested in Lung Care Across the WHO European Region? Applying a Monetary Value to Disability-Adjusted Life-Years Within the International Respiratory Coalition’s Lung Facts |
title_full_unstemmed | How Much Should be Invested in Lung Care Across the WHO European Region? Applying a Monetary Value to Disability-Adjusted Life-Years Within the International Respiratory Coalition’s Lung Facts |
title_short | How Much Should be Invested in Lung Care Across the WHO European Region? Applying a Monetary Value to Disability-Adjusted Life-Years Within the International Respiratory Coalition’s Lung Facts |
title_sort | how much should be invested in lung care across the who european region? applying a monetary value to disability-adjusted life-years within the international respiratory coalition’s lung facts |
topic | Practical Application |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232602/ https://www.ncbi.nlm.nih.gov/pubmed/37039953 http://dx.doi.org/10.1007/s40258-023-00802-y |
work_keys_str_mv | AT franklinmatthew howmuchshouldbeinvestedinlungcareacrossthewhoeuropeanregionapplyingamonetaryvaluetodisabilityadjustedlifeyearswithintheinternationalrespiratorycoalitionslungfacts AT anguscolin howmuchshouldbeinvestedinlungcareacrossthewhoeuropeanregionapplyingamonetaryvaluetodisabilityadjustedlifeyearswithintheinternationalrespiratorycoalitionslungfacts AT weltetobias howmuchshouldbeinvestedinlungcareacrossthewhoeuropeanregionapplyingamonetaryvaluetodisabilityadjustedlifeyearswithintheinternationalrespiratorycoalitionslungfacts AT joosguy howmuchshouldbeinvestedinlungcareacrossthewhoeuropeanregionapplyingamonetaryvaluetodisabilityadjustedlifeyearswithintheinternationalrespiratorycoalitionslungfacts |